Description
Tesamorelin is a synthetic 44-residue peptide analog of growth hormone-releasing hormone (GHRH), produced through controlled peptide synthesis and stabilized by a trans-3-hexenoic acid modification at the N-terminus. It shares the core 44-amino-acid sequence of the endogenous releasing factor, and the N-terminal lipid modification is associated with extended serum persistence relative to native GHRH, which is a relevant characteristic for its use as a stable reference compound in laboratory settings.
In research applications, Tesamorelin is studied for its interaction with pituitary GHRH receptors and the downstream growth hormone / IGF-1 signaling cascade. It falls within the GHRH-analog category of secretagogue research compounds studied in this area.
Each batch is synthesized in a USA-registered GMP facility and characterized by HPLC and LC-MS.
All material is supplied strictly for laboratory research use.
Structural Information
| Property | Value |
|---|---|
| CAS Number | 901758-09-6 (acetate) |
| PubChem CID | 44147413 |
| Molecular Formula | C₂₂₃H₃₇₀N₇₂O₆₉S |
| Molecular Weight | 5196 g/mol |
| UNII | LGW5H38VE3 |


